Patients presenting late with HIV infection are at a higher risk of clinical events, are difficult to treat and have a higher mortality compared with those who present earlier. Indeed, being diagnosed too late for effective treatment has been shown to be a common scenario leading to death. The increased risk for opportunistic diseases and increased mortality are associated with low CD4 + T-cell counts. In addition to the detrimental effect on the health of the individual, late presentation also creates a significant societal burden because it is associated with increased risk of HIV transmission and increased resource use. All of these factors highlight the benefit of earlier testing, diagnosis and treatment of HIV.
Mortality risk is increased by late presentation
The defining immunological feature of patients who present late is that they begin treatment for HIV infection with low or very low CD4 + T-cell counts and, in many cases, have already progressed to AIDS [1, 2] . Elsewhere in this supplement, Johnson et al. [3] argue that all patients who present with a CD4 + T-cell count <200 cells/µl should be considered as late presenters. Low CD4 + T-cell counts specifically at the initiation of antiretroviral therapy (ART) have been associated with shorter life expectancy [4] , higher incidence of death or AIDS (Figure 1 ) [5] and higher rates of death due to AIDS, AIDS-defining malignancies, non-AIDS-defining malignancies, renal failure and liver disease [6] . Efforts should also be made to reduce the interval between HIV diagnosis and treatment initiation because delays at this stage can also worsen patient prognosis [7] .
Up to a third of HIV-related deaths might be a consequence of late diagnosis and delayed start of antiretroviral treatment [8] . Mortality is markedly higher in late presenters than in early presenters [9] , particularly in the short term (Figure 2 ) [9] [10] [11] . This difference is strongly associated with CD4 + T-cell count at presentation [12] [13] [14] . Lower nadir CD4 + T-cell counts are predictive of an increased risk of both AIDS and non-AIDS-related mortality [15, 16] . In one study of HIV-infected patients starting ART, mortality rates were 70.0 per 1,000 personyears at risk in patients with CD4 + T-cell <50 cells/µl compared with 3.2 in those with CD4 + T-cell ≥200 cells/ µl [12] . The Data Collection on Adverse Events of Anti-HIV Drugs study (D:A:D), which included over 23,000 HIV-infected patients, showed that a low latest or current CD4 + T-cell count was a strong predictor for liverrelated death (the most frequent cause of non-AIDSrelated death) and for other non-AIDS-related deaths, such as non-AIDS malignancies [16, 17] .
'Being diagnosed too late for effective treatment' was identified in a national audit of deaths among HIVinfected adults in the UK as a common scenario leading to death [8, 18] . Over 1 year, the audit found that late diagnosis of HIV accounted for 24.0% of 387 total deaths and 35.2% of 218 HIV-related deaths [8] . Studies from the UK [10, 19] , France [9, 11] , Spain [20] and the Netherlands [21] demonstrate the strong association between late presentation and an increased risk of mortality. In the UK, an estimated short-term mortality of 14% was reported for men having sex with men who were diagnosed late and 1% for men having sex with men who were not diagnosed late (adjusted odds ratio 10.8, 95% confidence interval [CI] 7.7-15.9) [19] . Another UK study of patients reporting heterosexual transmission of HIV demonstrated short-term mortality of 3.2% (491/15,523), the majority of which (87%) were diagnosed late [10] . In a French study that enrolled 6,805 patients newly diagnosed with HIV, there were 181 deaths in total and 65% of them (118 deaths [11] . In Spain, the issue of late presentation has been termed 'delayed HIV diagnosis' and, again, it is strongly associated with mortality (adjusted hazard ratio for death 5.2, 95% CI 1.9-14.5; note that multiple definitions of late presentation were used in this study) [20] . Finally, data from the Netherlands show that, of men starting treatment with CD4 + T-cell counts <50 cells/µl, 11% died in the first 3 years [21] . In comparison, there were no deaths in the group who started treatment at CD4 + T-cell count >350 cells/µl [21] .
Low CD4
+ T-cell count at presentation is associated with increased illness Patients presenting with low CD4 + T-cell counts also experience a greater burden of ill health, both AIDSrelated and non-AIDS related [2, 22, 23] .
A substudy of the Strategies for Management of Antiretroviral Therapy (SMART) trial compared the initiation of ART in HIV-infected patients at CD4 + T-cell counts >350 cells/µl (n=249) versus <250 cells/ µl (n=228) [22] . The incidence of opportunistic disease (fatal or non-fatal) and serious non-ADI (defined as cardiovascular, renal and hepatic disease, and non-AIDSdefining cancers) was significantly greater (P=0.002) in the group initiating ART at the lower CD4 + T-cell count [22] . The relationship between CD4 + T-cell count and the incidence of non-AIDS-defining malignancies (including Hodgkin's lymphoma, leukaemia, and cancer of the liver, lung, anus, colon and kidney) has also been examined [23] . Of 12,865 patients followed-up, 309 developed non-AIDS-defining malignancies and, again, the incidence was greater (P=0.0001) in those patients with low CD4 + T-cell counts [23] . A further study in patients with AIDS has shown that the lower the CD4 + T-cell level, the higher the relative risk of developing AIDS-defining malignancies, Kaposi's sarcoma or nonHodgkin's lymphoma [24] .
Further evidence shows that ADIs are strongly associated with low current CD4 + T-cell counts. Analysis of 10,341 HIV-infected patients revealed 684 patients with non-ADIs and 641 patients with ADIs, and the incidence of both was associated with low current CD4 + T-cell counts [25] . Compared with patients with a given CD4 + T-cell count, patients with a CD4 + T-cell count twice as high had a 23% lower incidence of non-ADIs and a 41% lower incidence of ADIs (both P<0.0001) [25] . In a study of late presenters defined by CD4 + T-cell counts <50 cells/µl, 57.3% were identified with an ADI within a week of presentation (versus only 7.2% of those diagnosed at CD4 + T-cell counts >50 cells/µl; P=0.0001), and a further 30 patients developed at least one new ADI over follow-up [2] . The most commonly diagnosed ADIs were tuberculosis, Pneumocystis carinii pneumonia, cytomegalovirus, toxoplasmosis and wasting syndrome [2] .
Treatment difficulties in patients with low CD4 + T-cell counts HIV-infected patients who present with low CD4 + T-cell counts are difficult to treat for a variety of reasons, explored in detail by Rockstroh et al. [26] elsewhere in this supplement. The risk of toxic effects of ART might be increased at low CD4 + T-cell counts, treatment failure is more common and immunological recovery to CD4 + T-cell count levels seen in uninfected patients is slower.
The introduction of combination ART has greatly reduced morbidity and mortality in HIV-infected patients, but long-term treatment has raised concerns about toxicities (such as increased incidence of cardiovascular disease, hepatotoxicity, renal disease and pancreatitis) [27] . Studies designed to examine the association between these toxicities and ART have frequently found that, in fact, HIV progression and low CD4 + T-cell counts are stronger predictors of toxicities such as anaemia, pancreatitis and neuropathy than the extent or type of ART treatment [27] [28] [29] [30] [31] [32] [33] [34] .
Anaemia is a frequent complication of HIV infection and is a commonly reported toxicity of ART. Two studies found a strong association between CD4 + T-cell counts <200 cells/µl at the initiation of ART and an increased incidence of anaemia (both drug-related and non drugrelated) [29, 33] . CD4 + T-cell count <200 cells/µl has been shown to be an additional risk factor for pancreatitis, which is a known adverse event of ART, particularly with didanosine [27, 32] . A further study examined the relationship of peripheral neuropathy to HIV treatment and found that, rather than any association with therapy, CD4 + T-cell counts at study entry <50 cells/µl were highly predictive of neuropathy (P=0.0001) [31] . Examination of the incidence of lipoatrophy in a group of ambulatory HIV-infected patients also revealed a strong association between CD4 + T-cell count and the incidence of lipoatrophy [28] . Among patients with low CD4 + T-cell counts (<50 cells/µl) at the initiation of ART, treatment-related gastrointestinal symptoms (particularly nausea and diarrhoea) were more common in patients treated with lopinavir/ritonavir than in patients who received atazanavir/ritonavir [34] . A lower CD4 + T-cell nadir count might also increase the risk of developing the metabolic syndrome during ART [35] .
There is evidence of a link between late presentation and risk of treatment failure. Lower CD4 + T-cell counts at initiation of ART have been associated with a higher probability of drug failure [36] . Despite this, it might be that patients with low CD4 + T-cell counts are more likely to persist with existing therapy: patients with a higher CD4 + T-cell count were more likely to discontinue ART due to toxicities in several studies [36] [37] [38] .
Those patients with lower CD4 + T-cell counts at the start of ART might also take longer to achieve so-called normal CD4 + T-cell counts and therefore spend longer periods of time with lower CD4 + T-cell counts and at risk of ADIs. Evidence suggests that the immunological response to ART is more rapid when baseline CD4 + T-cell count is higher [39] . In one study of patients who received 144 weeks of ART, patients with lower baseline CD4 + T-cell counts failed to increase their CD4 + T-cell count to the same level as those with higher baseline counts [40] . In a longer-term study (>5 years), patients with lower CD4 + T-cell counts continued to achieve significant increases in CD4 + T-cell count whilst their viral load was suppressed, but their absolute CD4 + T-cell levels remained consistently lower than those of patients who started with higher counts [41] . However, other studies have suggested that the rate and quality of immunological recovery is not worse in patients who present at very low CD4 + T-cell counts, but simply takes longer because there is more recovering to do than in patients who present at higher CD4 + T-cell counts [42, 43] .
Societal consequences of late presentation
Effects at the population level
The behaviour and characteristics of late-presenting patients can have a substantial impact on the HIV epidemic at the population level. Studies have shown that a diagnosis of HIV motivates a proportion of infected individuals to adopt behaviours that reduce the risk of infecting HIV-negative people. These include increased participation in needle exchange programmes, stopping sex work or stopping sexual relations [44] . Indeed, US data suggest that transmission rates might be more than three times lower in individuals who are aware they are HIV-positive [45] . Combined with the observation that increased viral load leads to increased transmission risk [46] , and the fact that late-presenting patients will tend to have greater viral load than patients presenting earlier ( Figure 3 ) [47] , this suggests that late presentation might contribute to an increased risk of HIV transmission. Further supporting the value of early initiation of ART, onward transmission of HIV is vastly reduced by provision of ART [48] . After 3 years of ART in ARTnaive, HIV-infected adults in Uganda, the estimated risk of HIV transmission declined by 92% from 45.7 to 4.2/1,000 person-years [48] .
As discussed in detail by Yazdanpanah et al. [49] elsewhere in this supplement, the difficulties of implementing early diagnosis and treatment of HIV are far from straightforward and frequently encompass wider social issues than medicine alone. Migrants from a country with a generalized HIV epidemic, such as sub-Saharan Africa, most frequently acquire infection from their country of origin and the majority of such migrants will present late [50] . Factors relating to late presentation of migrants within western Europe include language, cultural, socioeconomic and legal barriers to care [51] . Practical and political difficulties in addressing the issue of late presentation also exist in other hard-to-reach populations within western Europe, such as sex workers and injecting drug users [50] . Fear of diagnosis and stigma associated with HIV is another crucial factor that deters people from presenting early for HIV testing: one study found that Black Africans presenting for HIV testing were twice as likely as White people to be worried about future discrimination if they tested positive [51] . Fear of prosecution might be a further factor deterring some individuals from presenting for HIV testing, contributing to the unwelcome trend towards later presentation. At least 130 people have been convicted for transmitting or exposing another person to HIV infection [52] .
Economic impact of late presentation
The increased morbidity in late presenters constitutes a problem in terms of greater economic burden. The greater proportion of ADIs occurring in patients presenting with low CD4 + T-cell counts tends to command a disproportionate share of hospital resources [2, 53, 54] .
European data relating to the economic impact of late diagnosis are scarce, although preliminary data reported from an analysis of the Swiss HIV Cohort Study suggest that late presentation is associated with increased costs: 11,991 Swiss francs with CD4 + T-cell counts 0-100 cells/ µl versus 8,569 Swiss francs with CD4 + T-cell counts >351 cells/µl [55] . More data are available from other developed nations and can be used to discuss possible cost implications within Europe. A Canadian study found that the mean annual cost of caring for and treating patients diagnosed late (CD4 + T-cell <200 cells/µl) in the year after diagnosis was at least twice as high as for early presenters (CD4 + T-cell >200 cells/µl) [53] . This difference was primarily due to increased HIV-related hospital costs and antiretroviral drug use. The excess cost was very much greater at low CD4 + T-cell counts and dropped rapidly as CD4 + T-cell count increased. Such findings highlight the potential economic benefits of routine HIV screening in identifying infected individuals before CD4 + T-cell levels have dropped significantly. A US study investigated the costs, benefits and cost-effectiveness of screening for HIV in healthcare settings during the era of highly active antiretroviral therapy [56] . HIV screening was found to be of similar cost effectiveness to other commonly accepted screening programmes and medical interventions, even when the prevalence of HIV infection in the screened populations was relatively low [56] .
A UK study has examined the use of clinical resources in the management of late presenters (CD4 + T-cell count <50 cells/µl). The study concluded that late presenters make large demands upon healthcare resources, particularly in the first few months after presentation [2] .
Conclusions
Late presentation for HIV infection is associated with increased risks of HIV-and non-HIV-related morbidity and mortality, worsened disease course and a greater burden for healthcare systems and payers. Numerous studies in general populations (including early and late presenters) have illustrated the importance of starting therapy before CD4 + T-cell counts drop too low [4, 6, 22, 57] . Earlier diagnosis of HIV infection will have an enormous impact in reducing illness and death associated with this disease. Initiatives to improve diagnosis of HIV at an earlier stage of disease progression are urgently needed.
